伊塔科纳酸促进了一个意想不到的瘤免疫逃生机制
Lara Haase1, Christian Frezza2
1Institute for Metabolomics in Ageing, Cluster of Excellence Cellular Stress Responses in Aging-associated Diseases (CECAD), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Cancer cell
|November 15, 2024
概括
与瘤相关的巨细胞产生抗微生物代谢物伊塔康酸. 癌细胞通过SLC13A3载体吸收这种伊塔科纳酸,从而增强它们对免疫检查点抑制剂的抵抗力.
科学领域:
- 免疫学 免疫学 免疫学
- 代谢过程中的代谢.
- 癌症生物学 癌症生物学
背景情况:
- 伊塔科纳酸是巨细胞在感染期间产生的关键代谢物,具有抗菌性质.
- 瘤微环境通常具有巨细胞,可以影响癌症的进展和治疗反应.
研究的目的:
- 研究瘤相关巨细胞 (TAMs) 产生的伊塔科纳酸在癌症中的作用.
- 确定癌细胞与TAM衍生的伊塔科纳酸相互作用的机制.
- 探索这种相互作用对免疫检查点抑制剂 (ICI) 疗效的影响.
主要方法:
- 对瘤组织中伊塔科纳酸盐水平的分析.
- 在癌细胞中识别 itaconate 载体.
- 评估癌细胞对ICI在伊塔科纳酸存在或不存在时的敏感性.
主要成果:
- 伊塔科纳酸是由瘤微环境中的TAMs产生的.
- 癌细胞利用溶解物载体家族13成员3 (SLC13A3) 载体吸收伊塔康酸.
- 癌细胞吸收伊塔科纳酸盐会对免疫检查点抑制剂产生抵抗力.
结论:
- 通过SLC13A3传输到癌细胞的TAM衍生伊塔科纳酸,促进对免疫检查点抑制剂的耐药性.
- 准itaconate-SLC13A3轴可能是克服癌症ICI耐药性的新策略.
相关概念视频
Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Cytotoxic T Cells-mediated Immune Response
849
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
849
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


